LONDON – Novartis AG hailed the results of its Paradigm trial of LCZ696 as "a historical moment in the treatment of heart failure," with the combined ACE/neprilysin inhibitor reducing deaths by 20 percent, cutting hospitalizations by 21 percent and offering better quality of life, compared to treatment with ACE inhibitor enalapril alone.